SINO BIOPHARMACEUTICAL News

Sino Biopharmaceutical Presents Findings of Anti-Tumor Drug at American Cancer Conference

Sino Biopharmaceutical (HKG:1177) unit invoX Pharma orally presented updated findings from an ongoing phase 1 study of FS222 at the 2024 annual meeting of the American Society of Clinical Oncology, a

MT NewswiresJun 5 06:56

Sino Biopharmaceutical Cuts Conversion Price of Euro-Denominated Bonds Due 2025

Sino Biopharmaceutical (HKG:1177) will slash the conversion price of its 750 million euros zero-coupon convertible bonds due 2025 to HK$11.86 from HK$12.06 per share on June 19, according to a Wednesd

MT NewswiresJun 5 06:21

Sino Biopharmaceutical: Li Mingqin Retired as Executive Director

Sino Biopharmaceutical: Li Mingqin Retired as Executive Director

Dow JonesJun 5 03:42

Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials

Sino Biopharmaceutical (HKG:1177) said a multi-center Phase III clinical study on Benmelstobart Injection in combination with Anlotinib Hydrochloride Capsules as a first-line treatment of advanced unr

MT NewswiresMay 24 00:15

Sino Biopharmaceutical's Breakthrough in Renal Cancer Treatment

TipRanksMay 23 06:37

Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%

Sino Biopharmaceutical (HKG:1177) said its category 1 innovative drug Benmelstobart Injection obtained approval for marketing from China's National Medical Products Administration (NMPA) as a first-li

MT NewswiresMay 9 02:44

Executive Chairwoman of the Board of Sino Biopharmaceutical Y. Y. Tse Buys 167% More Shares

Those following along with Sino Biopharmaceutical Limited (HKG:1177) will no doubt be intrigued by the recent purchase of shares by Y. Y. Tse, Executive Chairwoman of the Board of the company, who spe

Simply Wall StApr 21 19:30

Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug

Sino Biopharmaceutical's (HKG:1177) key clinical research for the registration of Rovadicitinib has met its primary endpoint, a Thursday filing on the Hong Kong bourse stated. The pharmaceutical compa

MT NewswiresApr 19 03:15

Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024

Sino Biopharmaceutical (HKG:1177) presented Phase-II Clinical Trial results for its new drug for non-small cell lung cancer (NSCLC) at the annual meeting of the American Association for Cancer Researc

MT NewswiresApr 10 19:20

Sino Biopharmaceutical Trustee Repurchases Shares

A trustee of Sino Biopharmaceutical (HKG:1177) bought back a further 6.8 million shares under its share award scheme for around HK$19.1 million or HK$2.83 apiece, a Monday filing on the Hong Kong bour

MT NewswiresApr 8 05:38

Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China

Sino Biopharmaceutical (HKG:1177) will develop and commercialize Boehringer Ingelheim's cancer treatments in mainland China under a strategic partnership agreement. The Chinese pharmaceutical company'

MT NewswiresApr 8 04:42

Bullish Sino Biopharmaceutical Insiders Loaded Up On CN¥133.6m Of Stock

Over the last year, a good number of insiders have significantly increased their holdings in Sino Biopharmaceutical Limited (HKG:1177). This is encouraging because it indicates that insiders are more

Simply Wall StApr 6 19:29